Antimicrobial Susceptibility Testing Market

Future Market Insights suggests that within the antimicrobial susceptibility testing landscape, the global urgency of antimicrobial resistance (AMR) is driving regulatory and clinical demand for rapid AST platforms that deliver actionable results in hours rather than the traditional 48 to 72 hours. Analysts identify ultra-rapid AST systems capable of sub-7-hour turnaround, led by Q-linea's ASTar platform and ShanX Medtech's 1-hour technology, as the central pivot point for the industry, effectively enabling same-day targeted antibiotic prescribing that reduces empiric broad-spectrum use and slows resistance development.